Evaluating Circulating microRNAs to Detect Germ Cell Cancer in Men with Small Testicular Masses or Post-Chemotherapy Retroperitoneal Masses

What this Trial Is About

Researchers are evaluating the use of circulating microRNAs to detect germ cell cancer in men with small testicular masses or residual tumors after chemotherapy. The study focuses on patients suitable for testis sparing surgery or retroperitoneal lymph node dissection. This observational study aims to improve diagnosis by comparing microRNA levels to traditional methods. Participants are divided into two groups those with small testicular lesions less than 2 cm and less than 30% testicular volume involvement, and those with post-chemotherapy retroperitoneal lymph node lesions greater than 1 cm for non-seminomatous or greater than 3 cm for seminomatous types. Blood samples will be taken before and after surgery to measure circulating microRNAs. The study includes evaluation at baseline and at four weeks to detect cancer presence, subtype, and any recurrence or persistence. During the study, participants will undergo blood tests to measure microRNA levels alongside other diagnostic procedures. Researchers will compare microRNA detection with frozen section examination results in the first group. The study assesses the accuracy of microRNAs in identifying germ cell cancer and monitors disease status over time. Participants involvement is based on scheduled assessments, with informed consent and follow-up at four weeks post-surgery.

Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses.